Yayın:
Even short-term telmisartan treatment ameliorated insulin resistance but had no influence on serum adiponectin and tumor necrosis factor-alpha levels in hypertensive patients with metabolic syndrome

dc.contributor.authorKıyıcı, Sinem
dc.contributor.authorGüçlü, Metin
dc.contributor.buuauthorBudak, Ferah
dc.contributor.buuauthorBUDAK, FERAH
dc.contributor.buuauthorSığırlı, Deniz
dc.contributor.buuauthorSIĞIRLI, DENİZ
dc.contributor.buuauthorTuncel, Ercan
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEndokrinoloji ve Metabolizma Ana Bilim Dalı
dc.contributor.orcid0000-0001-7625-9148
dc.contributor.researcheridIZP-9398-2023
dc.contributor.researcheridF-4657-2014
dc.contributor.researcheridAAA-7472-2021
dc.date.accessioned2024-11-26T05:29:16Z
dc.date.available2024-11-26T05:29:16Z
dc.date.issued2019-04-01
dc.description.abstractBackground: We investigated the effect of short-term telmisartan usage in addition to lifestyle changes such as diet and exercise on insulin resistance, lipid metabolism, and serum adiponectin and tumor necrosis factor-alpha (TNF-alpha) levels in hypertensive patients with metabolic syndrome (MetS). Methods:A total of 36 hypertensive patients with MetS were randomized to telmisartan and control groups in an open-labeled prospective study. Results: There were significant decreases in anthropometric variables of patients according to baseline measurements in both groups at the end of the study. Serum insulin level and insulin resistance assessed by homeostasis model assessment-insulin resistance were decreased significantly in the telmisartan group (P = 0.040 and P = 0.034, respectively) compared with the controls, while there was no statistically significant change in the lipid profiles of the two groups. Serum adiponectin level was increased by 19.1% +/- 41.7% in the telmisartan group, but intergroup analysis revealed no significant change. There was also no significant change in serum TNF-alpha level in either group. Conclusion: It has been observed that even short-term telmisartan treatment had favorable effects on insulin resistance and glucose metabolism compared with lifestyle changes alone. The fundamental effect of telmisartan treatment on insulin resistance renders it a good therapeutic option for hypertensive patients with MetS.
dc.identifier.doi10.1089/met.2018.0129
dc.identifier.endpage172
dc.identifier.issn1540-4196
dc.identifier.issue3
dc.identifier.startpage167
dc.identifier.urihttps://doi.org/10.1089/met.2018.0129
dc.identifier.urihttps://hdl.handle.net/11452/48456
dc.identifier.volume17
dc.identifier.wos000463021500006
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.journalMetabolic Syndrome And Related Disorders
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectType-2 diabetic-patients
dc.subjectIi receptor antagonist
dc.subjectSensitivity
dc.subjectAdipokines
dc.subjectObesity
dc.subjectParameters
dc.subjectProfile
dc.subjectRisk
dc.subjectTelmisartan
dc.subjectMetabolic syndrome
dc.subjectInsulin resistance
dc.subjectAdiponectin
dc.subjectTnf-alpha
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectMedicine, research & experimental
dc.subjectResearch & experimental medicine
dc.titleEven short-term telmisartan treatment ameliorated insulin resistance but had no influence on serum adiponectin and tumor necrosis factor-alpha levels in hypertensive patients with metabolic syndrome
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İmmunoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Biyoistatistik Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Endokrinoloji ve Metabolizma Ana Bilim Dalı
local.indexed.atWOS
relation.isAuthorOfPublication26fb3aa9-55a8-4fa3-8a4a-9c449958d4f5
relation.isAuthorOfPublicationf8b7b771-12ea-4f9a-889d-25079d8c862d
relation.isAuthorOfPublication.latestForDiscovery26fb3aa9-55a8-4fa3-8a4a-9c449958d4f5

Dosyalar